Ilsung Pharm (003120) - Total Liabilities

Latest as of December 2025: ₩16.67 Billion KRW ≈ $11.29 Million USD

Based on the latest financial reports, Ilsung Pharm (003120) has total liabilities worth ₩16.67 Billion KRW (≈ $11.29 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Ilsung Pharm - Total Liabilities Trend (2013–2025)

This chart illustrates how Ilsung Pharm's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Ilsung Pharm to evaluate short-term liquidity relative to the company's equity base.

Ilsung Pharm Competitors by Total Liabilities

The table below lists competitors of Ilsung Pharm ranked by their total liabilities.

Company Country Total Liabilities
Charoong Thai Wire and Cable Public Company Limited
BK:CTW
Thailand ฿2.03 Billion
KKB Engineering Berhad
KLSE:9466
Malaysia RM376.97 Million
BCP Investment Corp.
NASDAQ:BCIC
USA $350.91 Million
Aditya Birla Money Limited
NSE:BIRLAMONEY
India Rs31.66 Billion
Ersan Alisveris Hizmetleri & Gida Sanayi Ticaret AS
IS:KIMMR
Turkey TL4.65 Billion
Stars Microelectronics (Thailand) PCL
BK:SMT
Thailand ฿676.62 Million
BIOCELTIX S.A. ZY -10
F:XI3
Germany €2.36 Million
CURATIS N AG
SW:CURN
Switzerland CHF9.96 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Ilsung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ilsung Pharm (003120) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 17.47 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.04 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.04 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ilsung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ilsung Pharm (2013–2025)

The table below shows the annual total liabilities of Ilsung Pharm from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 ₩16.67 Billion
≈ $11.29 Million
+41.89%
2024-12-31 ₩11.75 Billion
≈ $7.96 Million
-67.77%
2023-12-31 ₩36.44 Billion
≈ $24.69 Million
-25.42%
2022-12-31 ₩48.85 Billion
≈ $33.11 Million
+91.78%
2021-12-31 ₩25.47 Billion
≈ $17.26 Million
+7.26%
2020-12-31 ₩23.75 Billion
≈ $16.09 Million
-1.16%
2019-12-31 ₩24.03 Billion
≈ $16.28 Million
+4.79%
2018-12-31 ₩22.93 Billion
≈ $15.54 Million
-6.93%
2017-12-31 ₩24.64 Billion
≈ $16.70 Million
+33.88%
2016-12-31 ₩18.40 Billion
≈ $12.47 Million
-62.20%
2015-12-31 ₩48.69 Billion
≈ $32.99 Million
-2.02%
2014-12-31 ₩49.69 Billion
≈ $33.67 Million
-0.45%
2013-12-31 ₩49.92 Billion
≈ $33.83 Million
--

About Ilsung Pharm

KO:003120 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$89.79 Million
₩132.50 Billion KRW
Market Cap Rank
#19708 Global
#1008 in Korea
Share Price
₩19440.00
Change (1 day)
-1.32%
52-Week Range
₩18300.00 - ₩28650.00
All Time High
₩31693.76
About

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, dige… Read more